Evidence map›Paper›PMID 34500549›Full record

ArticleMolecules (Basel, Switzerland)2021

Gadolinium-Based Paramagnetic Relaxation Enhancement Agent Enhances Sensitivity for NUS Multidimensional NMR-Based Metabolomics.

Chandrashekhar Honrao, Nathalie Teissier, Bo Zhang, Robert Powers, Elizabeth M O'Day

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Chandrashekhar HonraoOlaris, Inc., Waltham, MA 02451, USA.
Nathalie TeissierOlaris, Inc., Waltham, MA 02451, USA.
Bo ZhangOlaris, Inc., Waltham, MA 02451, USA.
Robert PowersDepartment of Chemistry, University of Nebraska-Lincoln, Lincoln, NE 68588, USA.ORCID 0000-0001-9948-6837
Elizabeth M O'DayOlaris, Inc., Waltham, MA 02451, USA.
University of Nebraska–Lincoln · US

Funding

Targeted mass spectrometry approaches to understand CART processing and recepter interactionsP20GM113126 · NIGMS · UNIVERSITY OF NEBRASKA LINCOLN · PI RAZAVI RIZI, MOHAMMAD · 2016 to 2025
$20.8M
National Science Foundation 1660921NIGMS NIH HHS P20 GM113126NIH HHS P20 GM113126
6 · The paper itself

Abstract

Gadolinium is a paramagnetic relaxation enhancement (PRE) agent that accelerates the relaxation of metabolite nuclei. In this study, we noted the ability of gadolinium to improve the sensitivity of two-dimensional, non-uniform sampled NMR spectral data collected from metabolomics samples. In time-equivalent experiments, the addition of gadolinium increased the mean signal intensity measurement and the signal-to-noise ratio for metabolite resonances in both standard and plasma samples. Gadolinium led to highly linear intensity measurements that correlated with metabolite concentrations. In the presence of gadolinium, we were able to detect a broad array of metabolites with a lower limit of detection and quantification in the low micromolar range. We also observed an increase in the repeatability of intensity measurements upon the addition of gadolinium. The results of this study suggest that the addition of a gadolinium-based PRE agent to metabolite samples can improve NMR-based metabolomics.

Indexed as

GadoliniumImage EnhancementMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMetabolomicsSignal-To-Noise RatioGadoliniumgadoliniummetabolomicsNMRparamagneticrelaxation

Identifiers

PMID34500549
PMCPMC8433644
OpenAlexW3194104043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.